OTCQX: RHHBY) announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity
10.1126/science.aaa3650 69 CoelhoF
Data extraction was performed on December 20, 2023, using codes from several coding classification systems, including the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Veterans Affairs (VA) Drug Classification System, and Anatomical Therapeutic Chemical (ATC) Classification System
It was first isolated and studied for its role in protecting and healing the gastrointestinal tract
SeekPeptides members have shared hundreds of protocol adjustments over time, and injection timing remains one of the simplest changes that yields the biggest improvements in tolerability